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Commentary
New scientiﬁc tools spawned by the genomics
revolution promise to improve our ability to
identify causative factors in human diseases.
These tools are expected to allow more rapid
screening of chemicals for toxic effects and to
provide mechanistic insight into a greater range
and earlier stage of adverse outcomes associated
with chemical exposures. Greater reliance on
computer-based models has already brought
remarkable advances in our ability to predict
disease progression. For example, Petricoin and
Liotta (2003) and Petricoin et al. (2002) have
demonstrated a diagnostic screening test based
on serum protein patterns for early detection of
ovarian cancer. But the reliance on computers
may make it more difﬁcult for scientists trained
in traditional toxicology to integrate this new
knowledge into existing paradigms. In addition
to barriers within the scientiﬁc community, the
emergence of these new technologies is taking
place in a political context that involves a vari-
ety of stakeholders with separate agendas. Thus,
despite major advances in the science and tech-
nology of these new toxicogenomics tools, these
scientiﬁc and political complexities threaten to
delay the use of toxicogenomics to further the
public interest or—worse—to advance its use
initially to weaken the regulation and safety of
widely used chemicals. In this article we high-
light three important issues in the development
of toxicogenomics and then report on a series
of expert interviews that give additional insights
into these and other critical questions.
Replace, Augment, or Reﬁne?
How will toxicogenomics be developed
and incorporated into testing and regula-
tory regimes? The often-stated promise of
toxicogenomics techniques is that they will
improve the screening of chemicals for toxic-
ity by being faster, cheaper, more accurate,
and more comprehensive than existing meth-
ods. But this promise is likely to be realized
only after a period of relatively expensive and
deliberate test validation and generation of
the massive reference databases needed to
make rigorous conclusions about test results.
Without proper study design, appropriate use
of controls, and multidisciplinary develop-
ment of standardized methods, acceptance of
new screening tests will be slow. In the
interim, the power of toxicogenomics is likely
to be applied piecemeal, with specific and
often proprietary toxicogenomics assays
developed and applied primarily to address
the problems faced by regulated industries.
The pharmaceutical industry has been
capitalizing on the strengths of toxicogenomics
to screen compounds for potential toxicity.
Large pharmaceutical companies have invested
in enormous databases of genomic responses to
known toxins and complex pattern recognition
software programs to screen test data against
these reference compounds (Hood 2003). This
reﬂects the enormous savings to the pharma-
ceutical industry from early identification of
the potential toxicity of a new product as well
as the fact that the drug development process
has a signiﬁcant backstop to toxicogenomics
screening in the form of extensive required
clinical testing. This backstop allows screening
for a limited set of toxic end points; early iden-
tification of drugs causing the limited set of
toxicities is still cost-effective, whereas the sub-
sequent rigorous clinical testing helps protect
the public by detecting other types of toxicity.
The chemical industry, on the other hand,
does not face any specific regulatory testing
requirements for new products. The Toxic
Substances Control Act of 1976 (TSCA)
(1976) stipulates that all known toxicity
information be disclosed in a premanufacture
notice, but it does not require that any spe-
ciﬁc testing be performed before manufacture
and marketing of a new chemical product.
Thus, the chemical industry has less of a reg-
ulatory incentive to prescreen chemicals
under development for potential toxicity.
Although the stated public positions of the
American Chemistry Council (ACC) and the
Chemical Industry Institute of Toxicology
Centers for Health Research (CIIT) describe a
desire to broaden the understanding of poten-
tial health risks of chemical products, the reg-
ulatory context and incentive structures are
leading to a focus on revising risk assessments
of existing products that the industry believes
overestimate true risks (e.g., Greenlee et al.
2003). Thus, the CIIT is applying toxicoge-
nomics and systems biology approaches to
compounds such as formaldehyde and chloro-
form in order to more fully elucidate cancer
mechanisms and potentially demonstrate non-
linearity of cancer dose responses. The CIIT
asserts that systems biology will provide a
“valuable payback” by reducing uncertainty
and that reduction in uncertainty will affect
environmental standard compliance costs, pre-
sumably by allowing more relaxed exposure
standards. The ACC’s Long-Range Research
Initiative, in response to recent funding cuts,
has redirected its academic program away
from exploratory toxicogenomics and systems
biology work but is continuing to fund the
CIIT to perform more focused work on exist-
ing chemicals (MacKenzie 2004). For now,
the stronger incentive for the chemical indus-
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erful screening tools suggests that the public
need for better screening tools will have to be
met elsewhere.
Phenotypic Anchoring: Scientiﬁc
Rigor or Scientiﬁc Shackling?
With the massive number of data points now
being monitored in gene and protein expres-
sion assays, some stakeholders are concerned
that changes in gene expression or protein lev-
els will be mistakenly interpreted as related to
adverse effects when in fact they are benign.
Within the chemical industry, some are call-
ing for linking toxicogenomics results to tra-
ditional toxicology tests (e.g., Henry 2002).
The implication is that changes in gene
expression should not be considered adverse
unless they can be directly related to out-
comes observed in traditional toxicology tests.
Although, on the face of it, this may seem
like a reasonable way to inject rigor into a
complicated process, placing overly strict lim-
itations on interpretation of gene expression
data ensures that only the end points now
assessed by traditional toxicology tests will be
the end points considered in the future. One
of the greatest promises of toxicogenomics is
the ability to assess toxicity more comprehen-
sively, picking up more subtle changes than
may be detected by histopathology or other
traditional detection methods. Tying the
interpretation of toxicogenomics testing so
strictly to traditional toxicity tests would keep
this promise from being realized because
information gained could be no more
comprehensive than current test methods.
Such scientific shackling of toxicogenomics
approaches must be prevented if the new
technologies are going to provide their
maximal beneﬁts.
Toxicogenomics Meets
Toxicogenetics
Can the study of the toxic effects of chemicals
be separated from the study of the genetic
mechanisms underlying variations in individ-
ual susceptibilities to those chemicals? In the
pharmaceutical arena, the observation that a
new drug for small cell lung cancer works
miraculously, but only for around 10% of
those affected, demonstrates the power to
identify critical variations in genetics and raises
the ethical issue of dividing populations into
those who benefit from new technology and
those who do not (Lynch et al. 2004).
Molecular epidemiology studies similarly show
that people with particular genotypes are at
increased risk of adverse health outcomes from
toxic exposures. Various metabolic polymor-
phisms have been shown to convey small dif-
ferences in risks for environmental exposures
(Kelada et al. 2003); more extreme examples,
whereby rare genotypes or combinations of
genotypes convey greatly increased risks, are
certainly possible. Current regulatory regimes
inconsistently address interindividual differ-
ences in susceptibility. The Clean Air Act of
1990 (1990) (and the Safe Drinking Water
Act Amendments of 1996 (1996) require
explicit consideration of sensitive subpopula-
tions in setting standards. TSCA, on the other
hand, is silent on the subject of individual sus-
ceptibility. Inadequate ethical and societal
frameworks for addressing susceptibility may
lead to public backlash against generating toxi-
cogenetic information or, worse, inappropriate
or discriminatory use of such information.
To gain further insight into the scientiﬁc
and political landscape of the new toxicology,
we interviewed 27 experts from a variety of
disciplines and sectors. Their views on the
current status of the different fields within
toxicogenomics, where they are going, and
what the barriers are to fulﬁlling their poten-
tial provide an opportunity to compare and
contrast different stakeholder viewpoints and
suggest roles for the public-interest science
community in promoting beneficial applica-
tions of toxicogenomics.
Materials and Methods
Interviewees were selected to represent five
different sectors involved in toxicogenomics:
government researchers, government regula-
tors, academic researchers, private-sector sci-
entists, and public-interest scientists. Of
34 experts initially identified for interviews,
two declined, saying they were not deeply
enough involved in the ﬁeld to speak about it,
and five could not be reached. The author
and one assistant conducted the interviews by
telephone, using a structured set of questions
as a guideline. We recorded and took notes
during the interviews and have complete tran-
scripts of each interview, except for four that
were not fully transcribed because of prob-
lems with recording.
We analyzed the transcripts by thoroughly
reviewing the text and identifying important
statements. Although the categories of
responses were partly determined by the spe-
ciﬁc questions, the answers often overlapped
with other issues. The categories of response
we used were a) general challenges to chemical
regulation and safety, b) impacts of toxico-
genomics on chemical regulation and safety,
c) applications closest to implementation,
d) applications furthest from implementation,
e) barriers to implementation, f) use of ani-
mals in testing, and g) actions that should be
taken by the environmental public-interest
community.
Comments were assigned to one of these
categories and put into a separate database to
facilitate comparison of the responses. The
responses then were grouped according to the
respondent’s sector.
Results
Question 1—What is the greatest challenge
facing chemical regulation and safety? Most
respondents mentioned long-standing limita-
tions of traditional toxicologic testing, speciﬁ-
cally the difﬁculties associated with using high
doses in animals to study low-dose effects in
humans. In addition, many of the respondents
mentioned the inability of traditional toxico-
logic testing to address issues of mixtures and
to differentiate easily between genotoxic and
nongenotoxic carcinogens. Finally, many
respondents referred to the fact that the large
number of chemicals used in commerce pre-
cludes obtaining enough data to assess their
risks, at least using current testing methods.
Several respondents pointed out other
challenges of the current system. One respon-
dent described the greatest challenge as per-
suading public-health professionals to recognize
(at least in that person’s opinion) that the toxic-
ity of common pharmaceuticals greatly
exceeded the toxicity of environmental chemi-
cals and that more efforts should be made to
reduce the public-health burden of adverse drug
reactions. Another felt that the need to over-
come the differing paradigms for cancer versus
noncancer end points was a signiﬁcant prob-
lem. Another respondent pointed to the lack of
good exposure data and generally poor risk
communication as problems.
Many respondents spoke about the same
uncertainties from different perspectives. One
academic talked about reaching the right bal-
ance in chemical regulation (presumably bal-
ancing need to protect public health with
needs to allow commerce to continue), whereas
some in academic research and the private sec-
tor were more concerned that the current use
of uncertainty factors was unscientific and
overly protective.
Question 2—Will the impacts of this new
technology on chemical regulation and safety
be positive or negative? Most of the respon-
dents felt that the development of new tech-
nology would be positive because more
information about biologic effects of chemi-
cals would allow more effective controls.
Many said the most positive impact would be
that toxicogenomics could help avoid the
need for dose and species extrapolation and
reduce the use of uncertainty factors. One
government researcher referred speciﬁcally to
obtaining information about controversial
beneficial effects of low-dose exposures to
compounds that are toxic at a higher dose.
Several also mentioned that toxicogenomics
methods might provide insights into whether
mixtures of chemicals produce additive,
synergistic, or antagonistic effects.
Several perspectives regarding potential
scientific benefits emerged. One respondent
pointed out that compared with traditional
toxicology tests, which are generally limited in
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toxicogenomics assays have a greater ability to
measure multiple dose–response curves for
multiple end points and multiple points in
time. This reinforces that much more infor-
mation will be available from a given experi-
ment, with both positive consequences (better
understanding of actual biologic responses)
and negative ones (difﬁculties of handling and
interpreting massively increased amounts of
data). Two respondents from industry pointed
to the benefit of greater confidence in the
safety (and lowered liability risk) of products.
Concerning potential negative impacts, several
respondents, including those within the indus-
try sector, expressed concern that the tech-
nologies were being forced too soon. Negative
consequences included misinterpreting the
data and making regulatory decisions before
there was sufﬁcient scientiﬁc certainty.
Question 3—What applications are closest
to implementation? Several applications and
types of information were cited as feasible in
the near term. Indeed, respondents noted sev-
eral applications that were presently under way
and had been used to generate data already
published. Many felt that gene and protein
arrays would yield useful information about
mechanisms and/or modes of action in the
near future. A few qualified this by limiting
the near-term applications to those related to
mechanisms of action that are already fairly
well characterized, especially those that are
mediated with known receptors.
Many respondents, especially those in the
pharmaceutical industry, mentioned the ability
to screen compounds for some types of toxicity
early in the drug development process. An
interesting area of divergence was whether these
same techniques could be applied to chemicals
in general. Several respondents from the acade-
mic and government research sectors felt that
the ability to obtain hazard-identiﬁcation infor-
mation from gene expression assays, at least for
some types of hazards, was close at hand. In the
private sector, some felt that such ability was
also close at hand, but others felt that lack of
reproducibility of assays prevented any effective
use of toxicogenomics data. For some respon-
dents, differences of opinion about the feasibil-
ity of toxicogenomics for chemical screening
were related to different concepts of what that
entailed. Those that had in mind screening for
recognized types of toxicity on chemicals with
some well-characterized structural analogs gen-
erally felt that such screening was close at hand.
Respondents who felt that screening was fur-
ther in the future generally conceptualized such
screening as involving completely unknown
chemicals and screening them comprehensively
for any type of toxicity.
Many respondents felt that the ability to
understand the importance of polymorphisms
for susceptibility to toxic compounds was
near. Different respondents, however, often
had different applications in mind when
speaking of susceptibility. Some were refer-
ring to the ability to understand and predict
an individual’s adverse reactions to pharma-
ceuticals, whereas others were referring to
identifying susceptibility factors for toxic
exposures in populations and individuals.
There was a further distinction between the
ability to identify speciﬁc genetic susceptibil-
ity factors for adverse outcomes from speciﬁc
drugs or toxic exposures and the ability to use
a more comprehensive genetic profile to
either tailor pharmaceutical interventions or
characterize a person’s overall susceptibility to
a variety of toxic exposures. Although many
respondents believed genetic susceptibility to
be a near-term prospect, those who were
referring to the more comprehensive applica-
tion of genetic susceptibility factors felt that
this application would not be available for
many years. Sector afﬁliation did not correlate
with the views on this topic, with private and
public sector respondents represented on both
sides of the disagreement.
Question 4—What applications are
furthest from implementation? Many respon-
dents considered the use of toxicogenomics
data quantitatively within risk assessments to
be far from implementation. Reasons for this
included the technical difﬁculty of getting the
assays to provide reliable, reproducible, quan-
titative dose–response information, as well as
the political and social difﬁculties of convinc-
ing regulatory agencies to change their prac-
tices. The ability to analyze complex mixtures
and long-term low-dose effects was also
considered unlikely to be realized soon.
A number of respondents placed the abil-
ity to model complex biologic systems as being
at least 5–10 years away. This theme encom-
passed the potential to link gene expression
changes to specific biologic pathways that
includes higher levels of biologic organization,
from protein expression through pathology, as
well as the promise of in silico modeling and
the ability to test chemicals for toxicity with-
out the use of animals. No respondents felt
that these promises of toxicogenomics were
near. Two individuals mentioned related con-
cepts that were far in the future: the ability to
generate complete proteomic proﬁles and the
ability to use the entire genome in gene
expression microarrays.
Finally, metabonomics and metabolomics
were singled out as approaches not yet ready
for full implementation. The respondents
noted that the technologies to make compre-
hensive analyses of metabolites were in rela-
tively early stages of development, and that
therefore the ability to standardize and analyze
the data from these types of experiments was
just now developing. The inability to perform
comprehensive metabolite assays was related
to the difficulty of developing complex
biologic systems models.
Several concepts or applications were men-
tioned by only one or two respondents. One
respondent opined that the ability to intervene
clinically to address early signs of toxicologic
insult was far off. Other one-time mentions
included interspecies extrapolation and under-
standing the mechanisms of neurotoxicity.
Question 5—What are the main barriers
to implementation? Respondents offered
numerous answers to this question. Their
responses could be separated into those that
were primarily technical, relating either to the
development of the laboratory technology
itself or to the analysis and interpretation of
data, and those that were primarily sociopoliti-
cal, including barriers within the community
of scientists and regulators developing toxico-
genomics as well as barriers within society
at large.
One frequently mentioned technical barrier
was the high cost of generating the data neces-
sary to understand, standardize, and validate
toxicogenomics results and methods. There was
some disagreement as to whether the govern-
ment was investing sufﬁcient ﬁnancial resources
in toxicogenomics research to meet this need,
but there was considerable agreement that a
massive amount of data needs to be generated
in the early stages of implementation to provide
the understanding and context necessary for
reliably interpreting individual experiments.
Related to this, many respondents noted
that the amount of data generated by the
toxicogenomics experiments was itself a barrier
to the development and standardization of
methods. Many mentioned that the methods,
software, and hardware necessary to handle
the massive amounts of data were being devel-
oped but were relatively new to most molecu-
lar biologists. In addition to the sheer quantity
of data generated by toxicogenomics assays,
many respondents also expressed concerns that
the quality of data was a barrier. Respondents
expressed concern about appropriate study
design, the reproducibility of results across dif-
ferent laboratories and the different assays and
reagents used.
A critical, frequently mentioned technical
barrier was the ability to separate important
changes from background “noise.” Different
aspects of this issue include the need to
distinguish between important signals of a
much smaller magnitude than some benign
changes in gene and protein expression that
might occur simultaneously. In addition,
changes are being monitored in tens of thou-
sands of genes and hundreds of proteins at
once, increasing the statistical probability of
many false positives and false negatives. The
difficulty in identifying true responses has
underlined the particular importance of nega-
tive controls in toxicogenomics research.
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defining significant changes in gene and
protein expression extremely complicated.
In addition to these technical barriers, the
respondents mentioned numerous sociopoliti-
cal barriers. Some of these were intertwined
with the technical details of toxicogenomics
and had to do with scientiﬁc culture and the
nature of the research and regulatory institu-
tions involved. For example, one frequently
mentioned barrier is the difﬁculty in achieving
the effective multidisciplinary collaboration
needed to develop toxicogenomics effectively
and appropriately. This problem is not unique
to toxicogenomics and has always been a prob-
lem for environmental health and safety, but
certain aspects of toxicogenomics were high-
lighted as posing special challenges because of
the need for multidisciplinary work. For
example, several respondents noted that the
quantity and complexity of data analysis
requires more effective collaboration between
molecular biologists and computational biolo-
gists. Some respondents addressed this issue by
requiring training molecular biologists to learn
the programming that is necessary to analyze
their own data; others emphasized multi-
disciplinary input into study design to avoid
asking the wrong questions and failing to
generate the types of data needed to answer
speciﬁc questions.
Difficulty of persuading the scientific
community to change its methods for
approaching problems was a second sociopo-
litical barrier. Several respondents pointed out
that toxicologists tend to be conservative, to
adhere to “tried and true” laboratory methods
(i.e., traditional animal tests), and to be very
slow in adopting new methods. A few respon-
dents noted that this is especially true for
regulatory toxicologists employed in govern-
ment. A philosophical challenge constituted a
more complex barrier. Several respondents
spoke of moving from a paradigm of reduc-
tionism, in which scientists focus intently on
one gene or one mechanism to solve prob-
lems, to a broader paradigm of complex bio-
logic systems. Several stated that in making
this paradigm shift, scientists would need to
abandon the comfort of feeling that they
understand in detail what changes are occur-
ring in a gene or other component of a cell
and instead rely on computerized analysis of
changes in thousands of genes and hundreds
of proteins. Both the resistance to change and
the philosophical shift required were common
themes in the interviews.
Turning from the scientiﬁc community to
society at large, many respondents voiced
concerns that societal forces would hinder the
implementation and use of toxicogenomics
advances. The most frequently mentioned
was the concern that the development of
societal mechanisms for addressing the ethical,
legal, and social aspects of toxicogenomics (and
toxicogenetics) was lagging behind the tech-
nologic advances. This was mentioned in two
very different contexts. Many respondents
expressed concern that privacy concerns and
mistrust among the general public would
impede the development of methods to deter-
mine and understand susceptibility. Others
pointed to the lack of legal and regulatory
mechanisms that allow the increased use of
toxicogenomics data in regulatory matters.
Several maintained that without clarity and
some form of protection from premature
regulatory use, industries would be reluctant
to start generating and providing toxico-
genomics data in new chemical or drug appli-
cations. They pointed out that the U.S. Food
and Drug Administration was well ahead of
the U.S. Environmental Protection Agency
(EPA) and had developed a safe-harbor sys-
tem that was indeed facilitating the develop-
ment of genomics and proteomics data in
new drug applications. Several respondents
mentioned the related concept of incentives,
noting that the chemical industry had little
incentive to spend money to develop toxi-
cogenomics data, that the pharmaceutical
industry had little incentive to share data-
bases, and that the health care industry in
general had little incentive to make a large
investment in research that would lead to
prevention rather than therapeutics.
Many respondents’ comments were more
appropriately categorized as ways of reducing
barriers rather than identifying the barriers
themselves. One respondent observed that the
private sector, with its greater flexibility and
focus, might be better suited to foster multi-
disciplinarity. Several comments addressed
steps the government needed to take, speciﬁ-
cally the U.S. EPA. Suggestions included the
need to invest more in data generation now
that methods for gene arrays have been estab-
lished and the need to train and develop
U.S. EPA staff to be able to understand and
use these data better. One respondent focused
on the need to fund work that would better
integrate data generation and the bioinfor-
matics work needed to interpret the data.
Last, several respondents emphasized the need
for better educating toxicologists and scien-
tists (and recruiting scientists already familiar
with toxicogenomics to do that educating) as
well as educating the general public before
toxicogenomics is applied more widely.
Question 6—How will the development of
toxicogenomics affect the use of animals for
testing? There was a moderate amount of
disagreement about how the development of
toxicogenomics would affect the use of ani-
mals in testing in both the short and the long
term. Most respondents felt that the use of
animals would not decrease over the short
term; some believed that their use would not
be much affected; and others predicted an
increase, perhaps sizable. Over the long term,
more respondents felt that overall use of ani-
mals would decrease, although some predicted
that the use of animals in testing would still be
necessary, even as toxicogenomics methods
supplied ever-greater amounts of information.
In general, most respondents agreed that the
promise of toxicogenomics to reduce the use
of animals in testing would not be realized in
the near term, and none felt that in vitro toxi-
cogenomics methods would ever completely
replace animals in toxicologic testing.
Question 7—What are appropriate roles
for the environmental public-interest commu-
nity? The most common response to this
question was some form of public education.
Many respondents felt that a critical role of
the environmental public-interest community
was to provide reliable information to the
public about the benefits and limitations of
toxicogenomics. Many respondents, particu-
larly those from the academic and private sec-
tors, emphasized the need to “paint an even
picture” and to avoid overselling the potential
of toxicogenomics. Respondents from the
nonproﬁt sector emphasized the need to pro-
mote development of toxicogenomics applica-
tions as a means of improving our ability to
detect toxicity and regulate toxic chemicals.
The second most common response
involved science advocacy, either advocating
for adequate funding or ensuring that the
interpretation of results would be both scientif-
ically rigorous and in the public interest. Some
respondents mentioned the need to persuade
government agencies to conduct the extensive
basic science research required at this stage,
whereas others stressed the need to engage poli-
cymakers in setting research agendas and
ensuring that basic science research served pol-
icy needs. Many respondents emphasized the
need for the public-interest community to be
represented by scientists familiar with the tech-
nology and science issues so that the public-
interest community could be part of the
discussions between government agencies and
industry and could play a watchdog role in
those discussions. This was true for both
the science-monitoring and the regulatory-
monitoring themes. Several respondents
underscored this by pointing to the need to
provide a counterpoint to industry’s inﬂuence
on the process of determining how toxico-
genomics information would be incorporated
into risk assessment and regulatory processes.
Finally, many respondents mentioned the
need for a brokering function among indus-
try interests, academics, and government
staff, particularly with regard to the ethical,
legal, and social implications of toxicoge-
nomics. Several respondents cited the need to
convene a workshop on this topic, led by
public-interest groups.
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Discussion
Interviewees expressed widespread agreement
that the new toxicology promises a signiﬁcant
increase in the amount of information available
on toxic effects of chemicals. Nearly all respon-
dents felt this would ultimately make it easier
to identify and predict which chemicals cause
adverse effects at environmentally relevant
doses. And nearly all welcomed this improved
ability because they were frustrated by the limi-
tations of current toxicologic test batteries. For
some, the main frustration was the limited
ability of current toxicologic test batteries to
assess subtle forms of toxicity that may occur at
low doses; for others, the main source of frus-
tration was the sense that extrapolations across
dose and species leads to overly cautious stan-
dard setting. It is critical that discussion of
implementing the new toxicology not get
bogged down in a false dichotomy of whether
the new will replace the old. Instead, the focus
should be on how scientists and regulators can
obtain the most information from these tech-
niques now and how best to incorporate results
from the new techniques in a progressive fash-
ion that builds the experience necessary to
make full use of this additional knowledge in
the future.
The interviews show that the promise of
the new toxicology will be realized only if a
set of obstacles can be overcome. Respondents
differed as to which obstacles were the most
important and how quickly they might be
overcome. Many of the obstacles identified
were technical in nature, whereas others were
political in nature. Public-interest scientists
have a role to play in overcoming both types
of obstacles. Advocacy for increased research
resources will help address technical obstacles.
Sociopolitical obstacles must be addressed
through public and policymaker education
and engagement in committees and stake-
holder processes.
The most commonly identified technical
needs were reﬁning computational methods to
be able to analyze vast, complex data sets, gen-
erating sufﬁcient data to be able to train predic-
tive toxicology models, and developing higher
throughput assays for proteins and metabolites.
Validation of assays and development of
standardized data reporting frameworks were
mentioned by some as significant obstacles,
but other experts felt that such significant
progress had been made in those areas that
they were no longer major problems, at least
for genomic data.
A recurrent sociopolitical obstacle men-
tioned by experts from many sectors was the
inherent inertia of current toxicologic prac-
tices. This related not only to the reluctance of
toxicologists and regulators to educate them-
selves about new toxicologic methods but also
the reluctance of scientists to rely more heavily
on computational analyses of complex pat-
terns of responses that cannot easily be under-
stood in terms of known mechanisms and
pathways. This conﬂict has been played out in
the literature in the context of clinical diagnos-
tics and will likely become more prominent in
debates about types of toxicogenomics data
that can be used in regulatory settings
(Diamandis et al. 2003). Along with pheno-
typic anchoring to existing end points, it is
essential that the use of toxicogenomics data in
a screening or regulatory setting not depend
exclusively on achieving complete understand-
ing of the functional implications of individ-
ual gene, protein, or metabolite changes.
Although scientific rigor is necessary for the
new toxicology to move forward, the scientiﬁc
and public-interest communities must ensure
that calls for rigor are not part of a strategy of
foot-dragging and stalling.
The issue of proprietary databases was
controversial. Several government and acade-
mic respondents maintained that information
produced by biotechnology companies is often
their sole commodity and thus there are strong
disincentives to full sharing of new and useful
data. Most respondents from the private sector
downplayed this limitation, saying that the
private sector was contributing signiﬁcantly to
open international databases and that the
amount of data withheld for proprietary rea-
sons was small. Landmark initiatives such as
the Chemical Effects in Biological Systems
knowledge base (http://cebs.niehs.nih.gov/)
sponsored by the National Institute of
Environmental Health Sciences will be limited
in their value if only a subset of developed data
are submitted to it. Clearly, this is an issue that
must be monitored by both the public and the
public-interest sectors.
The public-interest community has a
critical role in helping guide the application
of this powerful new science. As with all new
technologies, societal risks may accompany
societal beneﬁts. Toxicogenomics promises to
increase knowledge of biologic mechanisms
and reduce toxicologic uncertainty. However,
public-interest groups must engage in the
science-policy process to ensure that needless
barriers are not erected, that shortcuts are not
taken, and that public-health protection and
an individual’s privacy are not compromised.
To engage effectively, public-interest groups
must increase their capability in this new,
exciting, and complex toxicology.
REFERENCES
Clean Air Act of 1990. Public Law 101-549. 15 November 1990.
Diamandis E. 2003. Proteomic patterns in biological fluids: do
they represent the future of cancer diagnostics? Clin
Chem 49:1272–1275.
Greenlee WF, Connolly RB, Andersen ME. 2003. Who, what
where and why. Chem Bus Am Chem Council. 31(8):12–15.
Available: http://www.uslri.org/documents/cat_10/
doc_368.pdf [accessed 23 May 2005].
Henry C. 2002. Genomics and the Chemical Industry.
Presentation to the NRC Committee on Emerging Issues
and Data on Environmental Contaminants, 4 October 2002.
Washington, DC:National Academy of Sciences. Available:
http://dels.nas.edu/emergingissues/docs/Henry.pdf
[accessed 6 September 2004].
Hood E. 2003. Pharmacogenomics: the promise of personalized
medicine. Environ Health Perspect 111:A581–A589.
Kelada, SN, Eaton DL, Wang SS, Rothman NR, Khoury MJ.
2003. The role of genetic polymorphisms in environmental
health. Environ Health Perspect 111:1055–1064.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto
RA, Brannigan BW, et al. 2004. Activating mutations in the
epidermal growth factor receptor underlying responsive-
ness of non-small-cell lung cancer to gefitinib. N Engl J
Med 350(21):2129–2139.
MacKenzie A. 2004. Adjusting the LRI Commitment to Economic
realities. American Chemistry Council Long-Range
Research Initiative Update. Washington, DC:American
Chemical Society (Spring), 1.
Petricoin EF , Ardekani AM, Hitt BA, Levine PJ, Fusaro VA,
Steinberg SM, et al. 2002. Use of proteomic patterns in
serum to identify ovarian cancer. Lancet 359(9306):572–577.
Petricoin E III, Liotta LA. 2003. The vision for a new diagnostic
paradigm. Clin Chem 49:1276–1278.
Safe Drinking Water Act Amendments of 1996. Public Law 104-
182. 6 August 1996. 
Toxic Substances Control Act of 1976. Public Law 94-469.
11 October 1976. 